Metoprolol for tachycardia
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol for Tachycardia: Effectiveness and Safety
Metoprolol for Multifocal Atrial Tachycardia (MAT)
Metoprolol has been shown to be effective in treating multifocal atrial tachycardia, especially in patients with underlying cardiopulmonary illness. Studies report that both oral and intravenous metoprolol can significantly slow heart rate, with many patients converting to sinus rhythm—up to 68% in one study, often within hours of administration. Importantly, these benefits were achieved without significant adverse effects on blood pressure or respiratory function, even in patients with severe pulmonary disease. Additionally, metoprolol was associated with improved oxygenation in some cases. These findings suggest that metoprolol is a safe and effective option for MAT, including in patients with respiratory failure Hazard1987Arsura1987.
Comparison with Other Treatments for MAT
In direct comparisons, metoprolol has demonstrated greater effectiveness than verapamil and placebo for MAT. In a randomized, double-blind trial, 89% of patients responded to metoprolol, compared to 44% for verapamil and 20% for placebo. Notably, some patients who did not respond to verapamil did respond to metoprolol, highlighting its potential as a preferred agent in difficult cases. However, careful patient selection remains important Arsura1988Arsura1987.
Metoprolol for Supraventricular Tachycardia (SVT) and Atrial Fibrillation
Metoprolol is also used for rate control in supraventricular tachycardias, including atrial fibrillation. In emergency settings, metoprolol and diltiazem were found to be similarly effective for acute rate control at two hours post-administration. However, diltiazem was associated with a higher risk of hypotension, particularly diastolic hypotension, compared to metoprolol. This suggests metoprolol may be a safer choice for patients at risk of low blood pressure . Additionally, metoprolol has been successfully used to treat SVT caused by caffeine toxicity .
Metoprolol in Ventricular Tachycardia and Arrhythmias Post-Myocardial Infarction
For patients with ventricular tachycardia, especially those with inducible sustained monomorphic VT, adding metoprolol to class I antiarrhythmic drugs improved outcomes, making arrhythmias harder to induce or noninducible in a significant number of patients . In the context of acute myocardial infarction, metoprolol did not reduce less serious ventricular arrhythmias but did lower the incidence of life-threatening ventricular fibrillation and reduced the need for additional antiarrhythmic drugs. The antiarrhythmic effect was more evident in the later phase after infarction Rydén1983Murray1986.
Metoprolol for Postural Tachycardia Syndrome (POTS) in Children
Metoprolol is also used in pediatric patients with postural tachycardia syndrome (POTS). Predictive models using ECG and heart rate variability (HRV) indicators have been developed to identify which children are most likely to respond to metoprolol. These models have shown high accuracy, helping clinicians tailor therapy and improve outcomes for pediatric POTS patients Xu2023Wang2019.
Conclusion
Metoprolol is a versatile and effective beta-blocker for various forms of tachycardia, including multifocal atrial tachycardia, supraventricular tachycardia, ventricular tachycardia, and postural tachycardia syndrome. It is generally well-tolerated, with a favorable safety profile compared to some alternatives, and can be used in patients with complex comorbidities, including respiratory disease and after myocardial infarction. Predictive tools are emerging to further optimize its use, especially in pediatric populations.
Sources and full results
Most relevant research papers on this topic